Wordt geladen...
Immune checkpoint inhibitors in challenging populations
Immune checkpoint inhibitors, including those targeting the PD-1/PD-L1 and CTLA-4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice did not qualify fo...
Bewaard in:
| Gepubliceerd in: | Cancer |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5445005/ https://ncbi.nlm.nih.gov/pubmed/28241095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30642 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|